For independent infusion centers, ambulatory infusion suites, specialty practice infusion rooms and home infusion providers, where one biologic dose can carry more revenue than a week of office visits.
Get a free revenue cycle assessmentInfusion revenue cycle management is the financial control of an infusion program from referral and benefits investigation through prior authorization, drug acquisition, administration documentation, coding, claim submission, underpayment recovery and appeals. Medical billing starts when the claim is built; infusion revenue cycle management starts before the drug is ordered and ends when the last dollar is collected.
Almost no other outpatient specialty puts a five figure product and a time based service in the same claim. Medicare pays separately payable Part B drugs at 106% of average sales price under 42 CFR 414.904, and that limit refreshes quarterly while acquisition cost moves independently. The administration line beside it is paid by documented start and stop time. One number is set by a federal file, the other by a nurse writing a time in a flowsheet.
At the order, not the claim. A biologic series carries an authorization with a drug, a dose, a date range, a unit count and now a place of service. UnitedHealthcare commercial policy 2026D0121W lists hospital outpatient as the non preferred setting for provider administered drugs and approves it for no more than 6 months before reassessment. Cigna coverage policy 1605 prefers a non hospital affiliated infusion center or the home. When the schedule moves and the approval does not, the drug is in the patient before anyone knows the claim will not pay.
Under buy and bill the practice purchases the product, carries it and is reimbursed later at a lagged quarterly limit. A denied biologic claim is not a lost fee, it is a lost asset. That is why infusion programs fail on front end work rather than coding skill, and why 42% of practice managers saying nobody owns denial follow up full time is a solvency problem.
Recognise three or more of these in your own numbers and the problem is the process, not the payer.
Get a free assessmentInfusion is organised not by practice size but by who owns the drug and who owns the room.
Freestanding chairs, often multi site, usually the preferred site of care in payer policy. Highest drug volume, thinnest margin per dose, most exposed to contract underpayment. State rules bite here: Vermont bars an insurer or pharmacy benefit manager from requiring white bagging under 8 V.S.A. 4089j, in force since 1 July 2024, so our Vermont programs carry a different authorization script from our Texas ones.
Rheumatology, neurology, gastroenterology, immunology and infectious disease rooms inside an office, where the infusion claim competes with the office visit workflow and loses. The same drug line problems run through oncology and hematology.
Paid under the outpatient prospective payment system, carrying the CY 2026 340B remedy offset of 0.5% on non drug payments, and the setting payers steer patients away from.
Medicare home infusion therapy pays per infusion drug administration calendar day, and only when a skilled professional is in the home that day.
The seven steps for an infusion program, each with the failure that costs infusion money.
Capture the drug, diagnosis, plan and whether the drug sits under the medical or pharmacy benefit. This is eligibility and prior authorization work, not reception work. Failure mode: the referral is booked as a visit, so nobody asks whether the plan will pay for the product at all.
Approve the drug, dose, unit count, date range and place of service. Failure mode: the approval covers the drug but not the setting, and a hospital outpatient chair turns a covered therapy into a write off.
Order the product against a scheduled patient. Failure mode: the dose is drawn before the authorization is confirmed, so a denial destroys inventory.
Record start time, stop time, route, sequence, administered amount and discarded amount. Failure mode: a blank stop time on a three hour infusion, which pays one hour and leaves the rest unbilled.
Apply the administration hierarchy, one initial code per encounter, the right sequential and concurrent codes, the drug code in dosage increments, the eleven digit NDC and JW or JZ. Certified medical coding separates a paid drug line from a returned one. Failure mode: two initial codes with no second access site documented.
Post to the contracted rate, not the allowed amount on the remittance. Failure mode: a short paid drug line posts as paid in full, and the average underpaid claim was short by $38 in the Luxen claim audit.
Work by root cause and by drug, which is how denials and AR recovery is structured. Failure mode: biologic denials queued behind injection denials, and claims aged past 180 days were recovered at 23% of dollar value.
Every ranking page on this search names revenue leakage. None puts a number under it. Organised by cause, with the governing rule and the Luxen audit finding. Dollars are modelled on a program collecting $2.6M a year at the audit error rates in the right hand column.
| Leak point | Codes or rule | What goes wrong | Annual dollars at risk | Luxen audit finding |
|---|---|---|---|---|
| Second initial administration code | 96365, 96413, 96409; NCCI Chapter XI, B.2 | Two initial codes, one encounter, no documented second access site | $31,000 | Billed on 7% of encounters across 12,400 infusion claims |
| Missing stop time | 96366, 96415 | The additional hour is never billed, so a three hour infusion pays as one | $44,000 | Time missing on 13% of infusions past the first hour |
| Drug units not in dosage increments | J1745, J9312, J1569 | Units billed as vials rather than the code increment | $88,000 | Mismatched on 9% of drug lines, understated in 6 of every 10 |
| Discarded drug not reported | JZ and JW on single dose containers | Zero waste lines without JZ, edited by Medicare since 2 October 2023 | $26,000 | Single dose vial lines missing a waste modifier are the most common returned claim |
| Site of care mismatch | UnitedHealthcare 2026D0121W; Cigna 1605 | Approval covers the drug but not the setting used | $67,000 | Setting did not match place of service on 8% of hospital outpatient claims |
| Expired authorization mid series | Payer unit and date range limits | A recurring biologic runs past the approved window | $59,000 | Expired before the dose on 12% of recurring biologic series |
| Silent contract underpayment | Contracted rate versus posted allowed amount | Short paid lines post as paid in full and are never appealed | $38,000 | The average underpaid claim was short by $38 |
We will tell you which of these leaks is open in your practice, free, in 30 minutes.
Book the reviewRead the two right hand columns differently. Typical names its source in the cell: the FY2025 CERT improper payment report where a federal figure exists, and pre onboarding medians from 410 Luxen practice billing reviews where none does. Target is Luxen client data across 38 practices, January 2024 to June 2026.
| Metric | Definition | Typical | Target |
|---|---|---|---|
| Days in AR | Days from service to payment posted | 44, pre onboarding median, Luxen billing reviews | 33 or fewer within 120 days |
| Net collection rate | Payments over charges net of contractual adjustments | 91.4% pre onboarding, Luxen client data | 97.8% by month six |
| Clean claim rate | Claims accepted on first submission | 89.6% pre onboarding, Luxen client data | 97.3% within 90 days |
| First pass denial rate | Claims denied on first adjudication | No direct federal figure; nearest marker is the 6.55% Medicare fee for service improper payment rate, CERT FY2025 | Below 6% on drug and administration lines |
| Cost to collect | Billing cost as a percentage of collections | No federal figure; the in house table below works out at 9.9% | 3% to 6% |
| Drug line accuracy rate | Units, NDC and waste matched to the administration record | 91% across 12,400 audited infusion claims | 98% or better at pre bill review |
Typical values come from the named federal source in the table intro. Target values come from Luxen client data.
Prior authorization in infusion is not one approval. It is four constraints on a single document, and any one of them can fail on its own: the drug, the dose and unit count, the date range, and increasingly the place of service. Three of the four are checked by most programs. The fourth is the one that now denies the claim.
UnitedHealthcare commercial medical benefit drug policy 2026D0121W, effective 1 September 2026, names hospital outpatient as the non preferred setting for provider administered drugs and states that non hospital outpatient infusion, physician offices, ambulatory infusion suites and home infusion are well accepted places of service. Continued hospital outpatient administration is approved for no more than 6 months before the patient is reassessed. Infliximab, ocrelizumab, immune globulin, vedolizumab, omalizumab and belimumab are named in that policy. Cigna coverage policy 1605, effective 15 June 2026, covers the hospital setting only when the label restricts it, when the patient has a history of unmanageable infusion reactions, or when a significant comorbidity precludes a less intensive site.
An approval with a unit count and an end date is a countdown. The tracker sits next to the infusion schedule and answers one question every morning: which doses in the next fourteen days fall outside their approved window, unit count or setting. An authorization expired before the scheduled dose on 12% of recurring biologic series in Luxen billing reviews, and every one was visible weeks earlier.
Treat the reauthorization date as a clinical deadline with an owner. When a denial lands, a peer to peer beats an appeal on speed, but file the appeal anyway to protect timely filing. Median appeal turnaround was 34 days from filing to payer decision in Luxen client data, roughly two infusion cycles.
Not the nurse and not the biller. 42% of practice managers said nobody owns denial follow up full time, and in infusion that vacancy sits between the schedule and the pharmacy, where the money is. Where new clinicians are joining the program, credentialing has to close before the first dose too.
The drug line is the business. Under buy and bill the practice purchases the product, holds it as inventory and is reimbursed after administration. Medicare pays separately payable Part B drugs at 106% of average sales price under 42 CFR 414.904, and 42 CFR 414.904(f) updates those limits quarterly. Acquisition price does not move on that schedule. The spread between the two is the margin, measured in single digit percentages on five figure doses.
A drug code bills in a defined dosage increment, so one dose is many units and the conversion is where money disappears quietly. Units did not match the code increment on 9% of drug lines in the 2026 Luxen Infusion Revenue Cycle Audit, and roughly six in ten of those were understated rather than overstated, which means the error never triggers a denial and never gets found. Verify every increment against the current CMS HCPCS quarterly update file rather than a coding website, and carry the eleven digit NDC on every commercial and Medicaid drug line.
JW reports the discarded amount from a single dose container or single use package separately payable under Part B, required since 1 January 2017. JZ reports that nothing was discarded; CMS made it mandatory from 1 July 2023 and began claim editing on 2 October 2023. A zero waste line carrying neither modifier is a returned claim. Not one competing page on this search names JZ at all.
On a drug line the difference between the contracted rate and the posted allowed amount is invisible unless someone has loaded the contract. Most infusion programs post the allowed amount from the remittance and call the claim closed, which means a short payment is recorded as a full one and the appeal window runs out untouched. The average underpaid claim was short by $38 in the Luxen claim audit. On a program running 14,000 paid lines a year that is not a rounding error, it is a salary. Load the contracts once and the detection is automatic from then on.
Home and pharmacy based infusion runs on a different payment mechanic. Infusion pharmacy revenue cycle management is a separate discipline, not a setting, and programs treating it as an extension of the chair lose money on both sides.
The Medicare home infusion therapy services benefit has been live since 1 January 2021 under section 5012 of the 21st Century Cures Act. It pays for professional services, training and education, and remote monitoring. CMS is explicit that professional services must be furnished in the home on the day of infusion drug administration, and the unit of payment is one infusion drug administration calendar day. A pump running at home with no skilled professional present that day generates no home infusion therapy payment at all, however well the drug claim is coded.
42 CFR 414.1550 sets three categories, each priced as the physician fee schedule equivalent of five hours of infusion in a physician office. Category 1 covers intravenous anti infectives, pain management, chelation and inotropic therapy. Category 2 covers subcutaneous infusions. Category 3 covers intravenous chemotherapy. Payment is 80% of the lesser of the actual charge or the fee schedule amount, adjusted by a geographic wage index. The initial visit pays more than subsequent visits, so miscategorising the first day of a therapy is a permanent loss on that episode.
42 CFR 423.100 excludes from the Part D drug definition any drug for which payment is available under Part A or Part B, regardless of deductible status or enrolment choices. That determination belongs at intake. Sent to the wrong benefit the claim is not underpaid, it is unpayable.
Dataset: the Luxen claim audit, from which 12,400 infusion and injectable drug administration claims were separated and re reviewed line by line against the administration record, the authorization and the contracted rate, January 2025 to June 2026. Authorization findings come from the Luxen billing reviews, 410 practice billing reviews over the same period. Counted: administration code selection against documented time and access sites, drug units against the code increment, waste modifier presence, place of service against the approved setting, and paid amount against contract.
Cite this as: The 2026 Luxen Infusion Revenue Cycle Audit, 12,400 infusion and injectable drug claims, January 2025 to June 2026.
Three biologic service lines across four chairs, no single view of approvals against the schedule, AR growing while collections looked flat. Luxen loaded the payer contracts, connected authorization tracking to the infusion calendar including place of service, and added a pre bill reconciliation of drug units, NDC and waste against the administration record.
Reported by the group Chief Financial Officer. Figures from Luxen client data, 38 practices, January 2024 to June 2026.
Luxen client data (38 practices, January 2024 to June 2026), Luxen billing reviews (410 practice billing reviews, January 2025 to June 2026) and the Luxen Practice Manager Survey 2026 (March 2026, 286 practice managers):
Worked for an infusion center with $2,625,000 in annual net collectible charges. Every input is stated.
Days in AR falling from 54 to 33 is 21 days of working capital returned. Every 10 days removed from AR released a median $41,000 in cash in Luxen billing reviews, so 21 days is roughly $86,100 released once. Practices reviewing AR ageing monthly carried 12 fewer days in AR, free to anyone who opens the report.
Want this arithmetic run on your own collections and denial rate?
Run my numbersNobody on this search publishes a number, so here is ours. Luxen charges 3% to 6% of collections for infusion revenue cycle management. Month to month, 30 days notice, no setup fee, no exit fee.
Eligibility and benefits verification, prior authorization and site of care tracking, certified coding, submission, posting to contract, underpayment recovery, denials and appeals, patient statements, and a denial report grouped by drug and root cause, as full service medical billing. BAA signed before anyone touches a record.
Not one page competing on this search compares the two costs. For a program collecting $2.6M a year, with in house figures from practices that shared payroll data in Luxen billing reviews.
| Line item | In-house | Luxen |
|---|---|---|
| Two billers and one authorization coordinator, fully loaded | $186,000 | Included |
| Certified coder, half time | $38,000 | Included |
| Billing software and clearinghouse | $9,600 | Included |
| Denial rework and appeals, 11 staff hours a week | $19,448 | Included |
| Coverage when a biller leaves | Open roles take a median 67 days | No gap |
| Annual total | $253,048 | $102,690 at 4% of collections |
A single site with one biologic, one payer and a biller who has run it for a decade does not need a partner. Bring one in when a second site or product arrives, or when the answer to who owns denial follow up is nobody. Comparing options in your state, start with our medical billing companies directory.
People ask which the top five revenue cycle companies in the country are. Wrong question: the answer changes with drug mix and payer mix. Score candidates instead. Ten points per item, seventy is a pass.
Ask for the numbers behind every claim: sample size, period, what was counted.
Billing is a subset of the cycle: code the encounter, submit the claim, post the payment, appeal the denial. Revenue cycle management owns everything that decides whether the claim was ever going to pay.
A billing vendor receives a dose already given and works with what the chart holds. A revenue cycle partner is in the workflow before the drug is ordered: confirming the benefit, holding the authorization against the schedule, checking the approved setting, loading the contract. In most specialties that gap costs a fee. In infusion it costs the product. For the claim side in detail, see our infusion billing services.
You already have someone doing this, so switching is the decision.
Week one is the BAA, system access and a read only pass over open AR. The median gap between a signed BAA and the first claims worked, across Luxen clients, was 9 business days. First recovered payments landed a median of 17 days after work began. Nothing migrates: we work inside the practice management system and EHR you already run, which matters because 71% of practices that changed systems said collections dipped for six months or more.
Your existing AR is not abandoned at handover. Claims aged past 180 days were recovered at 23% of dollar value in Luxen client data, so the backlog is worked in parallel. Give your current vendor notice after access is confirmed, not before.
Infusion programs run on OncoEMR, Epic, eClinicalWorks, Athenahealth, WellSky CareTend, Nexus and CitusHealth, plus a pharmacy inventory system talking to none of them. We work inside what you already run. No migration: 38% of practice managers had changed system in the past five years and 71% of those said collections dipped for at least six months.
Referral intake and benefits investigation, prior authorization and site of care approval, drug acquisition, administration and charge capture, coding and claim scrubbing, payment posting and underpayment detection, then denials and AR follow up. Stages 2 and 5 cost the most, because a wrong setting or a second initial administration code cannot be fixed after the drug is given.
There is no fixed list, because the right partner depends on your drug mix and payer mix. Score candidates on seven things: drug line competence, authorization ownership including site of care, contract loading, denial reporting grouped by drug, published fee basis, working inside your existing system, and month to month exit terms. Missing denial reporting was the main reason given by 52% of practices that switched billing vendors.
In audited infusion claims the causes concentrate in four places: a second initial administration code with no documented second access site, which NCCI Policy Manual Chapter XI does not permit; a missing stop time that kills the additional hour code; drug units billed as vials rather than dosage increments; and a site of care that does not match the approved setting. The site of care mismatch alone appeared on 8% of hospital outpatient claims in the 2026 Luxen Infusion Revenue Cycle Audit.
Luxen charges 3% to 6% of collections, with drug volume, authorization workload, payer mix and site count setting where you land. For a program collecting $2.6M a year, a fully staffed in house billing and authorization team costs about $253,048 annually against $102,690 at a 4% fee.
Across Luxen clients the median gap between a signed BAA and the first claims worked was 9 business days, and first recovered payments landed a median of 17 days after work began. Clean claim rate gains show inside 90 days, where the median rose from 89.6% to 97.3%. Days in AR settle by month four.
Billing works the claim after the dose is given: coding, submission, posting and appeals. Revenue cycle management owns the decisions that determine whether the claim could ever pay, starting at the referral with the benefit check, the authorization, the approved place of service and the contracted rate. In infusion, where the practice buys the drug before it bills for it, that gap costs the product rather than a fee.
A free 30 minute review of your AR ageing and denial reasons. We tell you what is recoverable and what it would take. No deck, no commitment, no fee.
Book a free revenue cycle assessment%20(1).avif)
